Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
NVAX Stock Chart & Stats
$8.01
-$1.22(-11.32%)
At close: 4:00 PM EST
$8.01
-$1.22(-11.32%)
Day’s Range― - ―
52-Week Range$5.01 - $10.64
Previous CloseN/A
Volume4.15M
Average Volume (3M)3.62M
Market Cap
$1.30B
Enterprise Value$885.03M
Total Cash (Recent Filing)$762.89M
Total Debt (Recent Filing)$251.14M
Price to Earnings (P/E)4.5
Beta1.88
Next Earnings
Mar 04, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding162,499,000
10 Day Avg. Volume4,965,563
30 Day Avg. Volume3,622,203
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-1.96
Price to Sales (P/S)1.79
P/FCF Ratio-12.20
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit0.90
Enterprise Value/Ebitda2.16
Forecast
1Y Price Target
$10.00Price Target Upside24.84% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)0.13
Revenue Forecast (FY)$459.02M
Bulls Say, Bears Say
Bulls Say
Asset Sale And Cost SavingsAgreement to transfer a Maryland facility to AstraZeneca is expected to provide about $59.8M in cash and generate roughly $230M in long-term savings, improving liquidity and operational efficiency.
Clinical Collaboration And Milestone PotentialPositive Phase 1/2 immunogenicity and safety results from Sanofi’s CIC program, combined with a potential $125M milestone tied to Phase 3 initiation, increase prospects for licensing and royalty revenues.
Revenue SurpriseAnalyst highlights a stronger-than-expected revenue print of $70.4M versus consensus $42M, which could boost investor confidence in the company’s commercial momentum.
Bears Say
Declining Prescription TrendsLatest U.S. prescription trends point to a declining COVID-19 vaccine market and seasonally weak scripts, with Nuvaxovid prescriptions down significantly, which could pressure sales and royalties.
Lower Booster Demand ExpectationsSurveyed payers and physicians anticipate about a 30% decline in adult booster doses, suggesting a reduced addressable market and downward pressure on future revenue forecasts.
Regulatory And Sentiment RiskRisk of more stringent requirements for seasonal vaccines together with persistent negative headlines may dampen uptake and investor sentiment, creating headwinds for market share recovery.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $5.01 and its highest was $10.64 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.30B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Mar 04, 2026 which is in 45 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 06, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$1.196 by -$0.054.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.49.
How many shares outstanding does Novavax have?
Novavax has 162,499,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$1.25 in its last earnings report, missing expectations of -$1.196. Following the earnings report the stock price went down -1.3%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (24.84% Upside)
$10.00 (24.84% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 979.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.10%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in strategic partnerships, cost reduction efforts, and financial improvements. However, there were notable challenges, including decreased product sales and a considerable net loss. The positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$10.00
▲(24.84% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Ownership Overview
0.38% Insiders
12.37% Mutual Funds
0.01% Other Institutional Investors
68.30% Public Companies and Individual Investors